trimethoprim has been researched along with trimetrexate in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (14.75) | 18.7374 |
| 1990's | 31 (50.82) | 18.2507 |
| 2000's | 14 (22.95) | 29.6817 |
| 2010's | 7 (11.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
| Forsch, RA; Queener, SF; Rosowsky, A | 1 |
| Baccanari, DP; Boytos, CM; Chan, JH; Hong, JS; Joyner, SS; Kuyper, LF; Rudolph, SK; Tansik, RL | 1 |
| Gangjee, A; Kothare, M; Queener, SF; Zaveri, N | 1 |
| Gangjee, A; Kisliuk, RL; Queener, SF; Vasudevan, A | 2 |
| Gangjee, A; Mavandadi, F; McGuire, JJ; Queener, SF | 1 |
| Mota, CE; Queener, SF; Rosowsky, A; Wright, JE | 1 |
| Bertino, JR; Ercikan-Abali, E; Mota, CE; Queener, SF; Rosowsky, A; Waltham, M | 1 |
| Barrows, LR; Gangjee, A; Kisliuk, RL; Queener, SF; Shi, J | 1 |
| Broom, AD; Francom, P; Gangjee, A; Queener, SF; Zhu, Y | 1 |
| Baccanari, DP; Boytos, CM; Caddell, JM; Comley, JC; Friedman, HS; Hunter, RN; Jones, ML; Joyner, SS; Knick, V; Kuyper, LF; Rudolph, SK; Stables, JN; Tansik, RL; Wilson, HR | 1 |
| Borotz, SE; Carter, RL; Hosmer, CA; Johnson, CA; Krauth, CA; Pfefferkorn, ER; Piper, JR; Queener, SF | 1 |
| Devraj, R; Gangjee, A; Queener, SF | 1 |
| Gangjee, A; Mavandadi, F; Queener, SF | 1 |
| Papoulis, AT; Queener, SF; Rosowsky, A | 1 |
| Cody, V; Galitsky, N; Gangjee, A; Guo, X; Luft, JR; Pangborn, W; Queener, SF | 1 |
| Elzein, E; Gangjee, A; McGuire, JJ; Queener, SF | 1 |
| Cody, V; Galitsky, N; Gangjee, A; Kisliuk, RL; Li, R; Luft, JR; Pangborn, W; Queener, SF; Vasudevan, A; Vidwans, AP | 1 |
| Gangjee, A; Queener, SF; Zhu, Y | 1 |
| Adair, O; Gangjee, A; Queener, SF | 1 |
| Cody, V; Fu, H; Galitsky, N; Papoulis, AT; Queener, SF; Rosowsky, A | 1 |
| Elzein, E; Gangjee, A; Kisliuk, RL; McGuire, JJ; Queener, SF; Vidwans, A | 1 |
| Aqvist, J; Graffner-Nordberg, M; Hallberg, A; Kolmodin, K; Queener, SF | 1 |
| Gangjee, A; Kisliuk, RL; McGuire, JJ; Zeng, Y | 1 |
| Adair, OO; Gangjee, A; Queener, SF | 1 |
| Chan, DC; Fu, H; Queener, SF; Rosowsky, A | 1 |
| Gangjee, A; Kisliuk, RL; McGuire, JJ; Queener, SF; Talreja, T; Zeng, Y | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Gangjee, A; Jain, HD; Kisliuk, RL; Queener, SF | 1 |
| Adair, OO; Gangjee, A; Pagley, M; Queener, SF | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Borrmann, S; Kiara, SM; Masseno, V; Mwai, L; Nzila, A; Ochola, I; Okombo, J | 1 |
| Gangjee, A; Guo, X; Jain, HD; Kisliuk, RL; Phan, J; Queener, SF | 1 |
| Cody, V; Gangjee, A; Kisliuk, RL; Namjoshi, OA; Queener, SF; Raghavan, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barks, J; Brockman, A; Gould, J; Hopper, AT; Radke, JB; Sibley, LD; Thomas, S; Wise, A; Zou, Y | 1 |
| Cody, V; Gangjee, A; Pace, J; Queener, S; Shah, K | 1 |
| Feinberg, J; Sattler, FR | 1 |
| Vinogradov, NA | 1 |
| Costantino, M | 1 |
| Allegra, CJ; Beaver, J; Boarman, D; Chabner, B; Kovacs, JA; Lewis, M; Masur, H; Parrillo, JE | 1 |
| Chastang, C; Derouin, F | 1 |
| Montgomery, AB | 1 |
| McCormack, JJ; Tong, WP; Webster, LK | 1 |
| Allegra, CJ; Chabner, BA; Drake, J; Kovacs, JA; Lunde, M; Masur, H; Parrillo, JE; Swan, JC | 1 |
| Kovacs, JA; Masur, H | 1 |
| Allegra, CJ; Chabner, B; Drake, J; Kennedy, S; Kovacs, JA; Masur, H; Parrillo, JE; Swan, JC | 1 |
| Fischl, MA | 1 |
| Lizasoain, M; Lumbreras, C; Pastor, C | 1 |
| Akil, B; Baughman, R; Boylen, CT; Davis, R; Frame, P; Hughlett, C; Nichols, L; Sattler, FR; Shelton, B; Weiss, W | 1 |
| Briand, CM; Gilli, RM; Rimet, OS; Sari, JC; Sasso, SP | 1 |
| Briand, C; Gilli, R; Lopez, C; Sari, JC; Sasso, S | 1 |
| Bagnara, AS; Nott, SE | 1 |
| Korraa, H; Saadeh, C | 1 |
| Jia, Q; Kovacs, JA; Ma, L | 1 |
| Anderson, AC; Chan, DC | 1 |
| Bag, S; Degani, MS; Queener, SF; Tawari, NR | 1 |
| Cheng, YS; Sacchettini, JC | 1 |
9 review(s) available for trimethoprim and trimetrexate
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Diagnosis and treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Diagnosis, Differential; Humans; Pneumonia, Pneumocystis; Prognosis; Pyrimethamine; Respiration, Artificial; Sulfanilamides; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1991 |
Recent developments in the therapy and management of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Therapy, Combination; Humans; Pentamidine; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1989 |
Pneumocystis carinii pneumonia: therapy and prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Quinazolines; Recurrence; Sulfadiazine; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1988 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Humans; Pentamidine; Pneumonia, Pneumocystis; Quinazolines; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate; Zidovudine | 1988 |
[Current alternatives in the treatment of Pneumocystis carinii pneumonia in patients with AIDS].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Eflornithine; Humans; Naphthoquinones; Pneumonia, Pneumocystis; Primaquine; Trimethoprim; Trimetrexate | 1994 |
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Drug Combinations; Drug Hypersensitivity; Drug Resistance, Microbial; Humans; Leucovorin; Naphthoquinones; Pentamidine; Pneumonia, Pneumocystis; Primaquine; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1996 |
Towards species-specific antifolates.
Topics: Amino Acid Sequence; Animals; Antimalarials; Drug Design; Folic Acid Antagonists; Humans; Molecular Sequence Data; Plasmodium falciparum; Pneumocystis carinii; Pteridines; Pyrimethamine; Pyrimidines; Sequence Alignment; Species Specificity; Tetrahydrofolate Dehydrogenase; Trimethoprim; Trimetrexate | 2006 |
2 trial(s) available for trimethoprim and trimetrexate
| Article | Year |
|---|---|
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Humans; Pentamidine; Pneumonia, Pneumocystis; Quinazolines; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate; Zidovudine | 1988 |
Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/0
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Child; Clinical Protocols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Pneumonia, Pneumocystis; Prospective Studies; Sulfamethoxazole; Treatment Outcome; Trimethoprim; Trimetrexate | 1994 |
51 other study(ies) available for trimethoprim and trimetrexate
| Article | Year |
|---|---|
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Chromatography, Thin Layer; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Pneumocystis; Pyrimidines; Rats; Spectrophotometry, Infrared; Toxoplasma | 1995 |
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
Topics: Animals; Antifungal Agents; Candida albicans; Drug Design; Folic Acid Antagonists; Humans; Mice; Pyrimethamine; Pyrimidines; Quinazolines; Recombinant Proteins; Structure-Activity Relationship; Trimethoprim; Trimetrexate | 1995 |
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
Topics: Animals; Antineoplastic Agents; Drug Design; Folic Acid Antagonists; Liver; Pneumocystis; Quinazolines; Rats; Structure-Activity Relationship; Toxoplasma | 1995 |
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Pneumocystis; Pyrimidines; Rats; Toxoplasma | 1995 |
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
Topics: Folic Acid Antagonists; Humans; Peptide Synthases; Pyrimidines; Tumor Cells, Cultured | 1995 |
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
Topics: Animals; Folic Acid Antagonists; Humans; Pyrimidines; Rats; Structure-Activity Relationship; Trimetrexate | 1994 |
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Folic Acid Antagonists; Humans; In Vitro Techniques; Liver; Mutagenesis, Site-Directed; Pneumocystis; Quinazolines; Rats; Structure-Activity Relationship; Toxoplasma | 1995 |
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Folic Acid Antagonists; Fungal Proteins; Humans; Liver; Mice; Molecular Conformation; Neoplasms, Experimental; Oxidation-Reduction; Pneumocystis; Pneumocystis Infections; Protozoan Proteins; Pyrimidines; Rats; Structure-Activity Relationship; Toxoplasma | 1993 |
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
Topics: Animals; Folic Acid; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Methylation; Pneumocystis; Rats; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Ultraviolet; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1996 |
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Candidiasis; Cell Division; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Mice, SCID; Models, Molecular; Molecular Conformation; Molecular Structure; Molecular Weight; Pneumonia, Pneumocystis; Protein Structure, Secondary; Quinazolines; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1996 |
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Topics: Animals; Anti-Infective Agents; Folic Acid Antagonists; Opportunistic Infections; Pneumocystis; Pneumonia, Pneumocystis; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis; Trimetrexate | 1996 |
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Liver; Mice; Molecular Structure; Neoplasms, Experimental; Pneumocystis; Pyrimidines; Rats; Recombinant Proteins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1996 |
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Liver; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1997 |
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Topics: Animals; Enzyme Inhibitors; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Methylation; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1997 |
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Topics: Animals; Folic Acid Antagonists; Liver; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimethoprim | 1998 |
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Liver; Models, Molecular; NAD; Naphthalenes; Phenylalanine; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1998 |
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimetabolites, Antineoplastic; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Glutamic Acid; Humans; Liver; Methotrexate; Mycobacterium avium; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Tumor Cells, Cultured | 1998 |
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Division; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Escherichia coli; Folic Acid Antagonists; Humans; Liver; Models, Molecular; Molecular Structure; NADP; Pneumocystis; Pyridines; Pyrimidines; Quinazolines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Tumor Cells, Cultured | 1998 |
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Inhibitory Concentration 50; Liver; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1998 |
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Folic Acid Antagonists; Humans; Mice; Mice, Inbred ICR; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Tumor Cells, Cultured | 1999 |
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
Topics: Animals; Antiparasitic Agents; Azepines; Drug Design; Folic Acid Antagonists; Humans; Liver; Models, Molecular; Mycobacterium avium; Pneumocystis; Pteridines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1999 |
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Drug Design; Folic Acid Antagonists; Glutamates; Guanine; Humans; Liver; Models, Molecular; Molecular Conformation; Pemetrexed; Pneumocystis; Pyrimidines; Pyrroles; Rats; Recombinant Proteins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Toxoplasma; Tumor Cells, Cultured | 2001 |
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
Topics: Animals; Esters; Folic Acid Antagonists; Humans; Ligands; Liver; Male; Models, Molecular; Pneumocystis; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Trimetrexate | 2001 |
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Drug Resistance, Neoplasm; Escherichia coli; Folic Acid Antagonists; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Molecular Conformation; Peptide Synthases; Pneumocystis; Recombinant Proteins; Species Specificity; Structure-Activity Relationship; Substrate Specificity; Tetrahydrofolate Dehydrogenase; Toxoplasma; Tumor Cells, Cultured | 2002 |
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cricetinae; Drug Screening Assays, Antitumor; Female; Folic Acid Antagonists; Humans; Mice; Mice, Inbred BALB C; Opportunistic Infections; Pneumocystis carinii; Pyridines; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis | 2003 |
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Topics: Animals; Azepines; Benzazepines; Folic Acid Antagonists; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pteridines; Rats; Solubility; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Water | 2004 |
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Escherichia coli; Folic Acid Antagonists; Humans; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pyrimidines; Pyrroles; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
Topics: Alkylation; Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Folic Acid Antagonists; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2008 |
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
Topics: Animals; Binding Sites; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Liver; Molecular Structure; Pneumocystis carinii; Quinazolines; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
Topics: Animals; Antimalarials; Folic Acid Antagonists; Genotype; Inhibitory Concentration 50; Kenya; Methotrexate; Mutation; Plasmodium falciparum; Polymerase Chain Reaction; Polymorphism, Genetic; Proguanil; Pyrimethamine; Tetrahydrofolate Dehydrogenase; Triazines; Trimethoprim; Trimetrexate | 2009 |
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
Topics: Animals; Crystallography, X-Ray; Enzyme Inhibitors; Escherichia coli; Folic Acid Antagonists; Glutamic Acid; Humans; Liver; Models, Molecular; Molecular Structure; Mycobacterium avium; Oxidation-Reduction; Pneumocystis carinii; Pyrimidines; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Toxoplasma | 2010 |
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
Topics: Amination; Aniline Compounds; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Humans; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pyridines; Pyrimidines; Recombinant Proteins; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2013 |
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
Topics: Animals; Antiparasitic Agents; Dogs; Female; Folic Acid Antagonists; Humans; Madin Darby Canine Kidney Cells; MCF-7 Cells; Mice; Molecular Structure; Piperazines; Pyrimidines; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis | 2019 |
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
Topics: Folic Acid Antagonists; Humans; Models, Molecular; Pneumocystis; Pneumocystis carinii; Pyrimidines; Structure-Activity Relationship; Trimethoprim | 2019 |
New developments in the treatment of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Aerosols; Dapsone; Drug Therapy, Combination; Eflornithine; Folic Acid Antagonists; Humans; Pentamidine; Pneumonia, Pneumocystis; Pyrimidines; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1992 |
[Some aspects of the treatment of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Dapsone; HIV Infections; Humans; Primaquine; Trimethoprim; Trimetrexate; Zidovudine | 1991 |
Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Topics: 4-Aminobenzoic Acid; Animals; Drug Combinations; Drug Evaluation, Preclinical; Folic Acid; Pneumocystis; Quinazolines; Rats; Sulfamethoxazole; Toxoplasma; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1989 |
In vitro effects of folate inhibitors on Toxoplasma gondii.
Topics: Animals; Enzyme-Linked Immunosorbent Assay; Folic Acid Antagonists; Microbial Sensitivity Tests; Pyrimethamine; Pyrimidines; Quinazolines; Sulfamethoxazole; Sulfisoxazole; Toxoplasma; Trimethoprim; Trimetrexate | 1989 |
Effect of trimethoprim, paracetamol and cimetidine on trimetrexate metabolism by rat perfused isolated livers.
Topics: Acetaminophen; Animals; Cimetidine; Drug Interactions; Folic Acid Antagonists; In Vitro Techniques; Liver; Male; Quinazolines; Rats; Rats, Inbred Strains; Trimethoprim; Trimetrexate | 1987 |
Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Topics: Animals; Cells, Cultured; Drug Therapy, Combination; Folic Acid Antagonists; Macrophages; Mice; Mice, Inbred BALB C; Pentamidine; Pyrimethamine; Quinazolines; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim; Trimetrexate | 1987 |
Treatment of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Folic Acid Antagonists; Humans; Methylprednisolone; Pentamidine; Pneumonia, Pneumocystis; Quinazolines; Recurrence; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Trimetrexate | 1987 |
Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Topics: Administration, Oral; Animals; Drug Therapy, Combination; Folic Acid Antagonists; Injections, Subcutaneous; Male; Pneumonia, Pneumocystis; Quinazolines; Rats; Rats, Inbred Strains; Sulfamethoxazole; Trimethoprim; Trimetrexate | 1988 |
Thermodynamic study of dihydrofolate reductase inhibitor selectivity.
Topics: Animals; Escherichia coli; Folic Acid Antagonists; Methotrexate; Mice; NADP; Protein Folding; Temperature; Thermodynamics; Trimethoprim; Trimetrexate | 1994 |
Thermodynamic study of folate analogue binding to dihydrofolate reductases from different species.
Topics: Animals; Calorimetry; Cattle; Escherichia coli; Folic Acid Antagonists; Liver; Methotrexate; NADP; Oxidation-Reduction; Species Specificity; Tetrahydrofolate Dehydrogenase; Thermodynamics; Trimethoprim; Trimetrexate | 1993 |
The toxicity of antifolates in Babesia bovis.
Topics: Animals; Babesia bovis; Folic Acid; Folic Acid Antagonists; Pyrimethamine; Pyrimidines; Quinazolines; Trimethoprim; Trimetrexate | 1993 |
Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase.
Topics: Animals; Drug Evaluation, Preclinical; Folic Acid Antagonists; Humans; Pneumocystis; Pneumocystis Infections; Pyrimethamine; Rats; Saccharomyces cerevisiae; Tetrahydrofolate Dehydrogenase; Triazines; Trimethoprim; Trimetrexate | 2002 |
Synthesis and biological evaluation of biguanide and dihydrotriazine derivatives as potential inhibitors of dihydrofolate reductase of opportunistic microorganisms.
Topics: Animals; Biguanides; Computer Simulation; Drug Design; Folic Acid Antagonists; Liver; Microbial Sensitivity Tests; Mycobacterium avium; Opportunistic Infections; Pneumocystis carinii; Protein Binding; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Triazines; Trimethoprim; Trimetrexate | 2010 |
Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Topics: Aminosalicylic Acid; Antitubercular Agents; Bacterial Proteins; Catalytic Domain; Drug Resistance, Bacterial; Enzyme Inhibitors; Folic Acid Antagonists; Kinetics; Ligands; Models, Molecular; Molecular Conformation; Mycobacterium tuberculosis; NADP; Nucleotide Deaminases; Phylogeny; Recombinant Proteins; Tetrahydrofolate Dehydrogenase; Tetrahydrofolates; Trimethoprim; Trimetrexate | 2016 |